Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.

Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, Coleman PJ, Dimuzio JM, Ferrara M, Di Filippo M, Gates AT, Graham DJ, Harper S, Hazuda DJ, Huang Q, McHale C, Monteagudo E, Pucci V, Rowley M, Rudd MT, Soriano A, Stahlhut MW, Vacca JP, Olsen DB, Liverton NJ, Carroll SS.

Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7. doi: 10.1128/AAC.00324-12. Epub 2012 May 21. Erratum in: Antimicrob Agents Chemother. 2014 Aug;58(8):4995. Huang, Qian [added].

2.

Synthesis and characterization of NiSn dendrimer-encapsulated nanoparticles.

Gates AT, Nettleton EG, Myers VS, Crooks RM.

Langmuir. 2010 Aug 3;26(15):12994-9. doi: 10.1021/la102214q.

PMID:
20590140
3.

Lysine-based zwitterionic molecular micelle for simultaneous separation of acidic and basic proteins using open tubular capillary electrochromatography.

Moore L Jr, LeJeune ZM, Luces CA, Gates AT, Li M, El-Zahab B, Garno JC, Warner IM.

Anal Chem. 2010 May 15;82(10):3997-4005. doi: 10.1021/ac902723n.

4.

Mechanistic investigation of N-homocysteinylation-mediated protein-gold nanoconjugate assembly.

Gates AT, Moore L Jr, Sylvain MR, Jones CM, Lowry M, El-Zahab B, Robinson JW, Strongin RM, Warner IM.

Langmuir. 2009 Aug 18;25(16):9346-51. doi: 10.1021/la900798q.

5.

A limited group of class I histone deacetylases acts to repress human immunodeficiency virus type 1 expression.

Keedy KS, Archin NM, Gates AT, Espeseth A, Hazuda DJ, Margolis DM.

J Virol. 2009 May;83(10):4749-56. doi: 10.1128/JVI.02585-08. Epub 2009 Mar 11.

6.

Genome-scale RNAi screen for host factors required for HIV replication.

Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, Stec E, Ferrer M, Strulovici B, Hazuda DJ, Espeseth AS.

Cell Host Microbe. 2008 Nov 13;4(5):495-504. doi: 10.1016/j.chom.2008.10.004. Epub 2008 Oct 30.

7.

First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates.

Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, Hazuda D, Hochman JH, Holloway K, Jin L, Kahana J, Lai MT, Lineberger J, McGaughey G, Moore KP, Nantermet P, Pietrak B, Price EA, Rajapakse H, Stauffer S, Steinbeiser MA, Seabrook G, Selnick HG, Shi XP, Stanton MG, Swestock J, Tugusheva K, Tyler KX, Vacca JP, Wong J, Wu G, Xu M, Cook JJ, Simon AJ.

J Pharmacol Exp Ther. 2009 Jan;328(1):131-40. doi: 10.1124/jpet.108.143628. Epub 2008 Oct 14.

PMID:
18854490
8.

Hit selection with false discovery rate control in genome-scale RNAi screens.

Zhang XD, Kuan PF, Ferrer M, Shu X, Liu YC, Gates AT, Kunapuli P, Stec EM, Xu M, Marine SD, Holder DJ, Strulovici B, Heyse JF, Espeseth AS.

Nucleic Acids Res. 2008 Aug;36(14):4667-79. doi: 10.1093/nar/gkn435. Epub 2008 Jul 15.

9.

Gold nanoparticle sensor for homocysteine thiolactone-induced protein modification.

Gates AT, Fakayode SO, Lowry M, Ganea GM, Murugeshu A, Robinson JW, Strongin RM, Warner IM.

Langmuir. 2008 Apr 15;24(8):4107-13. doi: 10.1021/la7033142. Epub 2008 Mar 7.

10.

Capillary electrophoretic screening for the inhibition of homocysteine thiolactone-induced protein oligomerization.

Gates AT, Lowry M, Fletcher KA, Murugeshu A, Rusin O, Robinson JW, Strongin RM, Warner IM.

Anal Chem. 2007 Nov 1;79(21):8249-56. Epub 2007 Sep 29.

11.

ROCK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling.

Chapados R, Abe K, Ihida-Stansbury K, McKean D, Gates AT, Kern M, Merklinger S, Elliott J, Plant A, Shimokawa H, Jones PL.

Circ Res. 2006 Oct 13;99(8):837-44. Epub 2006 Sep 21.

PMID:
16990566
12.

The RNA-unwinding activity of hepatitis C virus non-structural protein 3 (NS3) is positively modulated by its protease domain.

Gu B, Pruss CM, Gates AT, Khandekar SS.

Protein Pept Lett. 2005 May;12(4):315-21.

PMID:
15907174
13.

Sequence requirements for the development of a chimeric HCV replicon system.

Gates AT, Sarisky RT, Gu B.

Virus Res. 2004 Mar 15;100(2):213-22.

PMID:
15019239
14.

Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor.

Nguyen TT, Gates AT, Gutshall LL, Johnston VK, Gu B, Duffy KJ, Sarisky RT.

Antimicrob Agents Chemother. 2003 Nov;47(11):3525-30.

15.

Replication studies using genotype 1a subgenomic hepatitis C virus replicons.

Gu B, Gates AT, Isken O, Behrens SE, Sarisky RT.

J Virol. 2003 May;77(9):5352-9.

16.

Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase.

Dhanak D, Duffy KJ, Johnston VK, Lin-Goerke J, Darcy M, Shaw AN, Gu B, Silverman C, Gates AT, Nonnemacher MR, Earnshaw DL, Casper DJ, Kaura A, Baker A, Greenwood C, Gutshall LL, Maley D, DelVecchio A, Macarron R, Hofmann GA, Alnoah Z, Cheng HY, Chan G, Khandekar S, Keenan RM, Sarisky RT.

J Biol Chem. 2002 Oct 11;277(41):38322-7. Epub 2002 Aug 6.

Supplemental Content

Loading ...
Support Center